Dupilumab for children with steroid-dependent or frequently relapsing nephrotic syndrome
Tests dupilumab against placebo in children with severe nephrotic syndrome.
Key facts
- Who runs it
- National University Hospital, Singapore
- Where
- Singapore2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Dupilumab Therapy in Nephrotic Syndrome in Children
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 66 people, planned
- Started
- 27 Nov 2025
- Expected to end
- 28 Feb 2028
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Dupilumab
- Placebo
- Co-intervention of Prednisolone wean during randomised controlled phase
- Dupilumab open label extension phase
- Co-intervention of Prednisolone wean during open label extension phase
- Record updated
- 5 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teens with nephrotic syndrome (a kidney condition that leaks protein into the urine). Their disease keeps coming back or depends on steroids. They must be in full remission now.
- Age
- 6 to 18 years at recruitment. The disease must have started between 1 and 18 years of age.
- Sex
- All sexes can join.
- Disease stage
- Idiopathic nephrotic syndrome (no known cause) that is steroid-dependent or relapses often. A full or partial relapse within the last 1 year that got better with more steroids. In complete remission at recruitment.
- Earlier treatment
- On oral prednisolone, with or without mycophenolate or levamisole, as maintenance for 6 months or more. Disease poorly controlled or steroid side effects on this therapy. No Rituximab or other B-cell depleting drugs within the last 1 year.
- Biomarker or test result
- Must be able to check urine protein daily with Albustix. Kidney function (eGFR) must not be below 60 ml/min/1.73m2.
Main reasons for not taking part
- Focal segmental glomerulosclerosis proven by biopsy
- Eye conditions, except refractive errors, squint or mild cataract
- Ongoing infection such as HIV, Hepatitis B, Hepatitis C or tuberculosis, or frequent infections
- Signs of worm infection or travel to areas where it is common, unless ruled out
- Pregnancy or plans to become pregnant
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age between 6 years old and 18 years old at the point of recruitment with idiopathic nephrotic syndrome with disease onset between 1-18 years old
- Steroid-dependent disease or frequently relapsing disease prior to commencement of maintenance immunosuppression
- On oral prednisolone +/- mycophenolate or levamisole only as maintenance therapy for 6 months or more, and with inadequate disease control or steroid toxicity on therapy
- Nephrotic relapse or partial relapse (clinical or biochemical) within the last 1 year either unprovoked or during prednisolone wean, and which responded to increase in steroids
- In complete remission at the time of recruitment
- Competent with, and compliant to, daily urine protein monitoring with Albustix
Who cannot take part
- Received Rituximab or other B-cell depleting agents within the last 1 year
- Known or suspected non-compliance to medication or follow-up
- Pre-existing ophthalmological conditions except refractive errors, squint or mild cataract
- Current symptoms of helminth infection or travel to endemic areas, unless helminth infection is excluded
- Known ongoing infection including HIV, Hepatitis B, Hepatitis C or tuberculosis, otherwise immunosuppressed or with frequent infections
- Major systemic conditions, i.e. ASA Physical Status III-IV
- Known hypersensitivity to dupilumab or any of its excipients
- eGFR (by Bedside Schwartz equation) <60 ml/min/1.73m2
- Biopsy proven focal segmental glomerulosclerosis
- Pregnancy or intention to become pregnant
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 18 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if dupilumab works to treat severe nephrotic syndrome in children. It will also learn about the safety of dupilumab.
Read full original descriptionShow less
The main questions it aims to answer are:
* Does dupilumab reduce the time to relapse of nephrotic syndrome? * What medical problems do participants have when taking dupilumab?
Researchers will compare dupilumab to a placebo (a look-alike substance that contains no drug) to see if dupilumab works to treat severe nephrotic syndrome.
Participants will:
* Receive an injection of dupilumab or placebo (just under the skin) every 2 weeks (if ≥30kg) or every 4 weeks (if <30kg) for 24 weeks (6 months) * Wean down their prednisolone dose after starting the injections of dupilumab or placebo * Visit the clinic once every 2 weeks for checkups and tests * Keep a nephrotic diary to record down the urine dipstick result each day, together with the dose of prednisolone taken
If protein returns in participant's urine, they will have completed the study at that point. However, if the participant is found to have received the placebo, they will be offered to receive dupilumab for up to 24 weeks.
The 3 groups in the trial
- DupilumabTreatment being tested
Participants in the experimental arm will receive subcutaneous Dupilumab for 24 weeks at the following weight-based doses, which are identical to doses used in the treatment of atopic dermatitis (higher than that for asthma), i.e. * Regime A (15 to \<30kg): 600mg once, then 300mg every 28 days x 5 doses. * Regime B (30 to \<60kg): 400mg once, then 200mg every 14 days x 11 doses. * Regime C (60kg or more): 600mg once, then 300mg every 14 days x 11 doses.
Treatment: Dupilumab and Co-intervention of Prednisolone wean during randomised controlled phase
- PlaceboPlacebo, for comparison
Participants in the control arm will receive a subcutaneous injection of matched placebo (normal saline) at the same dosing intervals as the experimental arm for 24 weeks.
Treatment: Placebo and Co-intervention of Prednisolone wean during randomised controlled phase
- Open label extension phaseOther group
On relapse, participants will be unmasked. Participants who were randomised to the placebo group will be invited to enrol into an open label extension phase. Participants will receive dupilumab in a regime identical to the experimental arm.
Treatment: Dupilumab open label extension phase and Co-intervention of Prednisolone wean during open label extension phase
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Singapore-Malaysian Renal Trials - Nephrotic Syndrome (SMART-NS): Dupilumab Maintenance Therapy for Steroid-dependent and Frequently Relapsing Nephrotic Syndrome
- Plain-language title
- Dupilumab for children with steroid-dependent or frequently relapsing nephrotic syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT07091175, who can take part
- Record updated
- 5 December 2025